课题基金 / 基金详情

EWS/FLI-1: TARGET FOR RADIOSENSITIZATION & GROWTH INHIBITION OF EWING TUMORS

EWS/FLI-1: TARGET FOR RADIOSENSITIZATION & GROWTH INHIBITION OF EWING TUMORS
EWS/FLI-1:放射增敏目标
批准号:
6651743
负责人:
VICENTE NOTARIO
金额:
$34.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-01 至 2007-06-30

项目摘要

项目成果

VICENTE NOTARIO的其他基金

相关文献

中文摘要
翻译
描述(申请人提供):尤文氏肉瘤(ES)是一种实性高度恶性肿瘤
英文摘要
DESCRIPTION (provided by applicant): Ewing's sarcoma (ES) is a solid highly malignant neoplasm of the bone and soft tissues. Most often it affects children and young adolescents, being the second most common malignant bone tumor in young adults. ES is formed by poorly differentiated round cells of neuroectodermal origin. Current ES treatment includes a combined modality with radiotherapy and chemotherapy. Clinically, ES tumors are generally responsive to such treatment, but the overall cure rate is low because ES is an aggressive osteolytic tumor that frequently presents with metastatic disease. ES cells are characterized for having, in nearly 100 percent of the cases a reciprocal translocation between chromosomes 11 and 22 or, much less frequently, 21 and 22. This translocation results in the synthesis in these cells of fusion proteins with their N-terminus encoded by EWS gene sequences and their C- terminus encoded by sequences of either the FLI-1 gene, most frequently, or the ERG gene, both members of the ETS family of transcription factors. There is a limited repertoire of fusion types, with those involving EWS/FLI-1 being most frequently detected in ES patients. We have found that down-regulation of EWS/FLI-1 in ES cells caused both growth inhibition and sensitization to apoptosis by ionizing radiation and chemotherapeutic agents. Our overall objective is to define antisense oligonucleotides targeted to the EWS/FLI-1 (or EWS/ERG) junction as highly specific therapeutic tools for ES management, because there are no target fusion sequences in normal cells. Our central hypothesis is that antisense EWS/FLI-1 oligonucleotides targeted to the translocation junction will specifically render ES cells sensitive to DNA-damaging agents and, in addition, will prevent the oncogenic activity of the EWS/FLI-1 protein product. Treatment with antisense EWS/FLI-1 oligonucleotides will have a dual effect, enhancing ES cell killing and down-regulating cellular neoplastic properties. Two specific aims are proposed, which include experiments designed to study the effects of antisense EWS/FLI-1 oligonucleotides in vitro, on cultures ES cell lines, and in vivo, on tumors induced in mice by injection of ES cells. These studies should advance technological and scientific understanding for the translational application of antisense EWS/FLI-1 oligonucleotides to ES treatment in the future.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom
  • 批准号:
    8081809
  • 项目类别:
  • 资助金额:
    $30.9万
  • 财政年份:
    2008
  • 负责人:
    VICENTE NOTARIO
  • 依托单位:
Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom
  • 批准号:
    8254320
  • 项目类别:
  • 资助金额:
    $30.9万
  • 财政年份:
    2008
  • 负责人:
    VICENTE NOTARIO
  • 依托单位:
Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom
  • 批准号:
    7649300
  • 项目类别:
  • 资助金额:
    $31.85万
  • 财政年份:
    2008
  • 负责人:
    VICENTE NOTARIO
  • 依托单位:
MECHANISMS OF RDIATION RESPONSE AND ADP RIBOSE METABOLISM
  • 批准号:
    6443860
  • 项目类别:
  • 资助金额:
    $34.88万
  • 财政年份:
    2001
  • 负责人:
    VICENTE NOTARIO
  • 依托单位: